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Cigarette smoking continues to be a major public health problem, and while smoking rates
in men have shown some decrease over the last few decades, smoking rates among girls
and young women are increasing. Practically all of the important aspects of cigarette smok-
ing and many effects of nicotine are sexually dimorphic (reviewed by Pogun and Yararbas,
2009). Women become addicted more easily than men, while finding it harder to quit.
Nicotine replacement appears to be less effective in women. This may be linked to the
observation that women are more sensitive than men to non-nicotine cues or ingredients
in cigarettes. The reasons for these sex differences are mostly unknown. Several lines of
evidence suggest that many of the reported sex differences related to cigarette smoking
may stem from the inhibitory effects of nicotine and other tobacco alkaloids on estrogen
synthesis via the enzyme aromatase (cyp19a gene product). Aromatase is the last enzyme
in estrogen biosynthesis, catalyzing the conversion of androgens to estrogens.This review
provides a summary of experimental evidence supporting brain aromatase as a potential
mediator and/or modulator of nicotine actions in the brain, contributing to sex differences in
smoking behavior. Additional research on the interaction between tobacco smoke, nicotine,
and aromatase may help devise new, sex specific methods for prevention and treatment
of smoking addiction.
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INTRODUCTION
Cigarette smoke and nicotine produce diverse behavioral and
physiological effects in the developing as well as the adult human
brain (Benowitz, 2008), including changes in cognition, anxiety,
and aggression. These effects are traditionally explained by an
interaction with nicotinic acetylcholine receptors (nAChR). How-
ever, some well established peripheral effects of smoking in women
are not easily explained by this mechanism. Specifically, female cig-
arette smokers reach menopause at an earlier age and have lower
plasma estrogen levels than non-smoking females (Daniell, 1972;
MacMahon et al., 1982; Nusbaum et al., 2000). Female smokers
are also at increased risk of osteoporosis, which is a well known
correlate of decreased peripheral estrogen levels (Daniell, 1972;
Pant and Shapiro, 2008; Korkor et al., 2009).
AROMATASE
Estrogen biosynthesis depends on the enzyme aromatase (Cyp19a
gene product, Figure 1), which irreversibly converts androgens
such as androstenedione and testosterone synthesized in both the
ovary and testes, to the estrogens estrone and estradiol, respec-
tively. The mechanism is depicted in Figure 2. In humans, the
gene is located on chromosome 15q21.1 and is composed of 10
exons. Among them, exons II–X encode the aromatase protein
and the 3′-untranslated region of the mRNA, whereas the tissue-
specific first exon is alternatively spliced giving rise to a differential
5′-untranslated region of the mRNA in different tissues. Corre-
spondingly, tissue-specific promoters are used for tissue-specific
regulation of the CYP19 gene expression (e.g., Kamat et al., 2002).
Aromatase has a molecular weight of 55 kDa, a K m for testosterone
ranging from ∼60 to ∼240 nmol and a K m for androstenedione
ranging from 0.1 to 30µM, depending on the source of the enzyme
and the lab performing the assay (e.g., Nakajin et al., 1986; Guet
et al., 1999; Cooke, 2002; Hong et al., 2007).
NICOTINE AND RELATED ALKALOIDS INHIBIT AROMATASE
IN VITRO
To explore the possible link between cigarette smoking and
decreased endogenous estrogens, Barbieri et al. (1986) examined
the effects of constituents of tobacco on estrogen production in
human choriocarcinoma cells and term placental microsomes.
In choriocarcinoma cell cultures, nicotine, cotinine (a major
metabolite of nicotine), and anabasine (a minor tobacco con-
stituent) all inhibited androstenedione conversion to estrogen in
a dose-dependent fashion at concentrations in the low micromo-
lar range. Removal of nicotine, cotinine, and anabasine from the
culture medium resulted in the complete reversal of the inhibition
of aromatase. Furthermore, a supraphysiologic concentration of
androstenedione (73µM) in the culture medium blocked the inhi-
bition of aromatase caused by nicotine, cotinine, and anabasine. In
preparations of term placental microsomes, nicotine, cotinine, and
anabasine also inhibited the conversion of testosterone to estro-
gen. Kinetic analysis demonstrated the inhibition to be competitive
with respect to the substrate. These findings suggest that tobacco
alkaloids exert a direct, competitive, and reversible inhibitory effect
on aromatase activity at micromolar concentrations (Barbieri
et al., 1986). Importantly, subsequent studies by another research
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group discovered additional tobacco constituents and nicotine
derivatives with a significantly higher (sub-micromolar concen-
trations) activity in peripheral tissues including human placenta,
similar to that of clinically useful aromatase inhibitors (Osawa
et al., 1990; Bullion et al., 1991; Kadohama et al., 1993). To date
there have been no published studies of the concentrations of nico-
tine or its analogs required for in vitro inhibition of aromatase in
brain cells including astrocytes, microglia, and neurons.
The objective of this review is to summarize recent findings
documenting the distribution of aromatase in the brain and its
inhibition by nicotine in vivo; and to examine the implications
these findings may have on our understanding of developmental
and acute effects of nicotine on brain physiology and behavior.
It is important to note that aromatase inhibition is expected to
be mostly similar but not identical to estrogen receptor blockade,
FIGURE 1 | Structure of aromatse. Crystallographic structure of the
human aromatase cytochrome P450 (rainbow colored cartoon,
N-terminus=blue, C-terminus= red) in complex with the cofactor
protoporphyrin IX (top) and the substrate androstenedione (bottom)
depicted as stick diagrams (carbon=white, oxygen= red, nitrogen=blue,
iron=orange; from Wikipedia).
since inhibition of aromatase not only lowers the absolute levels
of estrogens but also may increase testosterone and thus fur-
ther reduce the estrogen/testosterone ratio in males and females.
Due to sex differences in regional morphology, levels of estro-
gen, testosterone, and their receptors in the brain (e.g., Cahill,
2005), manipulation of aromatase activity is likely to have sexually
dimorphic functional outcomes. Therefore, this review is focused
on findings in smoking and in aromatase and aromatase inhibitors
rather than the vast body of literature related to effects of estro-
gen or testosterone on the brain, recently reviewed by McCall and
Singer (2012) and by McEwen et al. (2012).
AROMATASE IS EXPRESSED IN THE ADULT BRAIN AND
INHIBITED BY NICOTINE IN VIVO
BRAIN EXPRESSION OF AROMATASE
Aromatase expression is found in many brain regions in birds,
rodents, non-human primates, and humans (Roselli et al., 1998;
Roselli and Resko, 2001; Biegon et al., 2010b; recently reviewed in
Biegon et al., 2010b, 2012; Azcoitia et al., 2011). In rodents, the
highest concentration of aromatase were found in amygdala and
the bed nucleus of the stria terminalis (e.g., Takahashi et al., 2006)
with low though significant levels in other regions (e.g., Sierra
et al., 2003).
Non-invasive assessment of aromatase availability throughout
the primate brain has become possible following radiosynthe-
sis, initial primate studies (Lidstrom et al., 1998; Kim et al.,
2009; Biegon et al., 2010a), and validation in humans (Biegon
et al., 2010b) of a radiolabeled aromatase inhibitor suitable for
positron emission tomography (PET). PET studies in both rhe-
sus monkeys and baboons revealed that the highest levels of
aromatase were found in the amygdala and preoptic area while
the thalamus and medulla contained low levels (Lidstrom et al.,
1998; Roselli and Resko, 2001; Takahashi et al., 2006; Kim et al.,
2009).
The most comprehensive study of aromatase distribution in
the human brain to date, performed using PET and [11C]vorozole
(Biegon et al., 2010b), revealed a highly specific and hetero-
geneous pattern which appears to be unique to humans. The
highest levels were seen in the thalamus, though thalamic dis-
tribution was not uniform: within the thalamus, the highest levels
were found in the dorsomedial and pulvinar nuclei with lower
FIGURE 2 | Biosynthesis of estrgoens by aromatase. (A) General reaction for the conversion of testosterone to estradiol catalyzed by aromatase. (B)
Catalytic mechanism of aromatase. The methyl group is a oxidized and subsequently eliminated.
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density in reticular, lateral, and anterior-ventral thalamic nuclei
(Figure 3). Very high levels were also found in the paraventricular
hypothalamic nucleus.
FIGURE 3 | Regional distribution of aromatase in the living human
brain. Summed frames obtained from PET acquisitions over 90 min after
[11C]vorozole administration of a representative non-smoking subject were
pseudocolored using the rainbow spectrum, such that red regions
correspond with high density of radioactivity and blue corresponds to the
lowest densities. The PET images are overlaid on a gray-level structural (T1
weighted) MRI scan of the same subject. From left to right: coronal slice at
the level of amygdala and hypothalalmus; slice at the level of the medial
thalamus and; slice at the level of the medulla (inferior olive; from Biegon
et al., 2010b).
Moderately high levels of aromatase were noted in amygdala
and preoptic area/anterior hypothalamus and in the medulla (infe-
rior olive). Basal ganglia levels were relatively low, with visibly
higher levels in the ventral striatum/nucleus accumbens (Biegon
et al., 2010b). Labeled vorozole distributed to all cortical regions,
with hippocampus indistinguishable from the temporal cortex.
The distribution volume values derived from a two compartment
model (Gunn et al., 2001; Logan, 2003; Logan et al., 2011) in both
men and women (regardless of menstrual cycle) followed the rank
order: thalamus> amygdala= preoptic area>medulla (inferior
olive)> cortex= hippocampus, putamen, cerebellum, and white
matter.
Earlier published postmortem studies were limited to a small
number of preselected regions, although the combination of stud-
ies by different research groups and different methodologies sup-
port the notion that aromatase is ubiquitous in the human brain,
although only a few regions express high levels of the enzyme
(reviewed in Azcoitia et al., 2011 and Biegon et al., 2012).
To elaborate, aromatase gene expression was examined in post-
mortem samples from eight brain regions (Sasano et al., 1998).
The amount of aromatase mRNA determined by RT-PCR assay in
six cases (four men, two women) was highest in pons, thalamus,
hypothalamus, and hippocampus. Analysis of multiple exons 1
revealed that exons 1f, considered specific for brain, as well as
1b (fibroblast type) and 1d (gonadal type), were expressed in the
brain. Exons 1d and 1f tended to be utilized in hypothalamus,
thalamus, and amygdala. The amount of overall mRNA expres-
sion was also higher in hypothalamus, thalamus, and amygdala
than in other regions of the brain. There were no differences
of utilization of exons 1 and mRNA expression of aromatase
between female and male brain. The authors concluded that
their results demonstrate that aromatase is expressed widely in
human brain tissues in both men and women. The presence of
aromatase transcripts in human temporal cortex, frontal cortex,
and hippocampus was also confirmed by Stoffel-Wagner et al.
(1999).
Aromatase immunoreactivity was found in hypothalamus,
amygdala, preoptic area, and (cholinergic) ventral forebrain nuclei
(Ishunina et al., 2005) in humans. Additional studies confirmed
aromatase immunoreactivity in temporal cortex, hippocampus,
and prefrontal cortex (Yague et al., 2006, 2010). Immunohisto-
chemistry was also used to examine the cellular and subcellular
distribution of aromatase in the human brain, establishing the
presence of aromatase immunoreactivity in neurons as well as
in glia. Thus, cortical and hippocampal aromatase was detected
in pyramidal cells, granule cells, and interneurons; in perikarya,
dendrites, axons, and axon terminals (Naftolin et al., 1996; Yague
et al., 2006, 2010). The presence of glial aromatase was con-
firmed in prefrontal cortex, temporal cortex, and hippocam-
pus, where it was associated with astrocytes (Yague et al., 2006,
2010).
Aromatase enzymatic activity was first described in the fetal
human limbic system by Naftolin et al. (1971), followed by reports
on activity in the adult brain and temporal cortex (Naftolin et al.,
1996; Steckelbroeck et al., 1999). In agreement with the results
from other methods described above, there were no differences in
aromatase enzymatic activity between men and women and no
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significant effect of aging in these brain regions (Steckelbroeck
et al., 1999).
NICOTINE ADMINISTERED IN VIVO INHIBITS AROMATASE IN THE
BRAIN
Nicotine modulation of brain aromatase in vivo was first reported
by von Ziegler et al. (1991) in fetal and neonatal mice. After 1 or
2 weeks of prenatal exposure to 6 mg/kg nicotine delivered by an
osmotic minipump, aromatase activity in male forebrains was sig-
nificantly decreased at postnatal day 6, with no significant effects
in females. The authors initially reported that nicotine alters brain
aromatase activity only on postnatal day 6, the day when nor-
mal females show lower levels than normal males (von Ziegler
et al., 1991). In subsequent studies in rats, it was shown that both
nicotine and cotinine inhibited aromatase activity in the basal
forebrain of male fetuses. Nicotine was twice as effective as coti-
nine and the effects of the two drugs were additive (Sarasin et al.,
2003).
Using [11C]vorozole, we have recently shown that acute in vivo
exposure to nicotine doses which produced plasma levels simi-
lar to those found in smokers, resulted in significant region- and
dose-dependent decreases in aromatase availability in the female
baboon brain. The largest and most significant inhibition was
found in the amygdala, where intravenous injection of 0.03 mg/kg
nicotine reduced brain aromatase availability by ∼50% (Biegon
et al., 2010b; Figure 4).
FIGURE 4 | Effect of nicotine on brain aromatase availability in the
female baboon.Top: (A) Baboon brain MRI, coronal section at the level of
amygdala. S, striatum; P, preoptic area; A, amygdala. (B) Representative
baseline PET image coregistered with MRI. (C) PET image of same baboon
following low dose nicotine (0.015 mg/kg). (D) PET image following injection
of high dose (0.03 mg/kg) nicotine. PET images show averaged frames
acquired between 52.5 and 90 min after tracer injection, pseudocolored
using the rainbow spectrum, with purple indicating the lowest density and
red indicating the highest density of radioactivity (from Biegon et al., 2010a).
BRAIN EFFECTS OF NICOTINE: SIMILARITIES AND
DIFFERENCES WITH AROMATASE INHIBITION
The discovery of the ability of neuroendocrine tissues to aromatize
androgens to estrogens was crucial to the formulation of the arom-
atization hypothesis (Naftolin and Ryan, 1975; McEwen et al.,
1977), stating that testosterone synthesized by the fetal testis dif-
fuses into the male brain where it is locally aromatized to estradiol
and then initiates the process of masculinization, resulting, in
adults, in the capacity to express male-typical sexual behaviors
and high levels of aggression. In females, the aromatization process
affects such functions as mood and appetite.
Consequently, aromatase inhibition can have a variety of sex-
ually dimorphic effects on multiple domains including sexual
functioning, mood, and cognition but the nature and persistence
of the effects can vary greatly depending on the developmental
status during exposure. The sections below provide a review of
the brain effects of nicotine and aromatase inhibition. We high-
light developmental, “organizational” brain effects (i.e., effects of
maternal smoking during pregnancy) as well as effects of exposure
in adolescents and adults when available in the literature, with the
best supported similarities and differences summarized in Table 1.
SEXUAL BEHAVIOR
Prenatal nicotine exposure was shown to decrease male sex-
ual behavior and to demasculinize male offspring (Segarra and
Strand, 1989), paralleling the effects in aromatase “knock-out”
(ArKO), and prenatal treatment with AI. In adult males, acute
nicotine administration resulted in decreased intromission fre-
quency, though this occurred only at 1.6 mg/kg, the highest dose
tested (Retana-Marquez et al., 1993). Decreased sexual perfor-
mance was also self reported in men exposed to cigarette smoke
(Weisberg, 1985).
Studies (reviewed in Roselli et al., 2009) confirmed that male
copulation is severely impaired in ArKO domestic mice in which
the aromatase gene was selectively inactivated, consistent with
the role for aromatization in both the organizational and activa-
tional effects of testosterone. Testosterone administration did not
improve male sexual behavior in castrated ArKO adults, whereas
Table 1 | Similarities and differences in brain effects of nicotine and
aromatase inhibition.
Male Female
Nicotine AI Nicotine AI
Sexual behavior
Prenatal exposure Decrease Decrease Increase Increase
Adult exposure Decrease ? Decrease Decrease
Anxiety/Depression
Prenatal exposure No effect No effect Increase Increase
Adult exposure No effect No effect Decrease Increase
Hot flashes Increase Increase
Weight gain Decrease Decrease Decrease Increase
AI, aromatase inhibition. Nicotine refers to smoking as well as nicotine alone.
?, there is not enough data on males to justify an increase or decrease effect.
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combined treatment with estradiol and dihydrotestosterone
(a non-aromatizable androgen) almost completely restored
copulation behavior to levels observed in wild-type males. These
results suggest that estrogens derived from aromatization of testos-
terone exert major activation effects on coital behavior in male
C57Bl6 mice. The extent to which testosterone in men acts through
aromatization to estradiol, is not yet clear. In eugonadal men,
the estrogen receptor antagonist, tamoxifen, and the aromatase
inhibitor, testolactone, had no adverse sexual effects. Furthermore,
dihydrotestosterone was as effective as testosterone in maintain-
ing sexuality in hypogonadal men, suggesting that aromatase was
not involved (Gooren, 1985). The comparison of two men with
congenital aromatase deficiencies, one with accompanying hypog-
onadism, suggested that testosterone alone allows for a normal
sexual activity, but that there is a synergistic effect between testos-
terone and estradiol derived from aromatization. These findings
suggest that aromatization may be required in men for completely
normal sexual behavior, but that androgens are the main steroids
involved.
In human females, prenatal exposure to nicotine resulted in
a significant increase in same-sex orientation among female off-
spring (Ellis and Cole-Harding, 2001). The influence of aromatiza-
tion on female sexual behavior is less clear but studies in female rats
show that sexual behavior was enhanced by prenatal inhibition of
androgen aromatization (Clemens and Gladue, 1978). In humans,
gender role and sexual behavior are disrupted in girls with con-
genital adrenocortical hyperplasia, which increases testosterone
levels (see recent review by Barenbaum and Beltz, 2011). Acute
effects show that treatment in adult female rats increased lordosis
in estrogen-treated ovariectomized female rats (Fuxe et al., 1977;
Weaver and Clemens, 1987), but acute exposure to nicotine in
adult men and women significantly reduced sexual arousal (Harte
and Meston, 2008a,b). In addition, adult women given aromatase
inhibitors report a loss of libido (Mitwally and Casper,2003; Zivian
and Salgado, 2008). These few studies on the sexual behavior of
females may not be sufficient to establish a solid hypothesis on the
direction of effects.
AGGRESSION
Prenatal smoking exposure and high trait aggression are associated
variables in numerous animal and human studies, particularly
during adolescence (Escobedo et al., 1997). This effect has been
replicated in epidemiological studies and after controlling for
important variables of heritability as mother’s antisocial behav-
iors (Moffitt et al., 2008; Wakschlag et al., 2010). The observation
that tobacco smoke exposure inhibits brain monoamine oxidase
A (MAO A; Fowler et al., 1996), has led to the suggestion that the
mechanism responsible for aggressive behavior in the offspring of
females exposed to cigarette smoke during pregnancy is MAO A
inhibition (Wakschlag et al., 2010). Indeed brain MAO A activ-
ity predicts trait aggression at adulthood (Alia-Klein et al., 2008,
2009). An additional and perhaps interactive mechanism in the
effects of smoking on aggression is the inhibition of aromatase
and little is known about the interactive potential of chronic MAO
and aromatase inhibition.
Prenatal and developmental effects of smoking on aggres-
sion appear to be different than the acute effects of smoking
in adults. In adults, smoking appears to reduce irritability and
aggression. Furthermore, nicotine replacement therapy was found
useful in reduction of agitation and aggression in smokers with
schizophrenia (Allen et al., 2011).
Importantly, although numerous preclinical and clinical stud-
ies have shown that acute nicotine treatment reduces aggression,
smoking deprivation results in negative mood, aggression, and
hostility in adult rodents and humans (Schechter, 1974; Cherek,
1981). In a recent study, a lifetime history of cigarette smoking was
associated with high traits of aggression and impulsivity in healthy
and personality disorder participants and these effects may have
started during prenatal development (Dakwar et al., 2011).
The effects on females appear to be similar to males in that
smokers of both sexes exhibit negative emotionality as compared
to non-smokers; however, the data is suggestive that smoking
affects aggression in males more than in females, where it has a
primary effect on depression (Pogun and Yararbas, 2009).
Aggressive behavior, long thought to be controlled by testos-
terone, also appears to be strongly dependent on aromatization
and estrogen in both mammalian and non-mammalian species
(see review by Trainor et al., 2006). Estrogen has been shown to
modulate aggression in a variety of species. Although in most
cases estrogen increases the probability and intensity of male-on-
male aggressive behavior, there are exceptions in which estrogen
decreases the intensity of aggression. Thus, the duration of aggres-
sive behavior in resident-intruder tests was extremely low for ArKO
mice compared to wild-type mice and estradiol injections restored
aggression to wild-type levels. However, when the production of
estrogen was blocked by an AI (fadrozole) in California mice, the
males were more aggressive compared to controls, indicating that
production of estrogen is associated with reduced aggression in
California mice.
DEPRESSION AND ANXIETY
Developmental effects of prenatal smoking exposure increase the
risk for depression particularly in females. Female offspring of
rodents prenatally treated with nicotine show vulnerability during
adolescence to depression and early smoking onset; more so than
males (Romero and Chen, 2004; Vaglenova et al., 2004). Findings
from human and animal studies infer sex and region specific effects
and suggest a role for smoking in higher rates of depression, espe-
cially among adolescent females (Kandel et al., 1994; Cornelius and
Day, 2009). Smoking during pregnancy has psychological effects
on the mothers as well as their offspring. In a study of persistent
pregnant smokers, the smokers reported higher prenatal stress and
depression than non-persistent smokers or non-smokers (Eiden
et al., 2011). Women were also found to be more vulnerable to the
depressive symptoms of nicotine withdrawal (Gaffin et al., 2011).
Acutely, nicotine has been found to be more anxiolytic in female
than in male rats (Harrod et al., 2004), corroborating human stud-
ies which also document that females are more susceptible to the
effects of nicotine on anxiety (Pogun and Yararbas, 2009).
In males nicotine has been shown to produce antidepressant-
like responses in rats subjected to the forced swimming test,
a popular model of depression in rodents. While this effect is
not expected to reflect inhibition of aromatase, it is relevant to
note that orchiectomy abolished the antidepressant effect of nico-
tine and its restoration required supplementation with estradiol
(Bonilla-Jaime et al., 2010).
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Decreased aromatase availability appears to have sexually
dimorphic effects on depression and anxiety in rodents. ArKO
females displayed decreased active behaviors, such as struggling
and swimming, and increased passive behaviors, such as floating,
in repeated sessions of the forced swim test, indicating that these
females exhibit “depressive-like” symptoms (Dalla et al., 2004).
This effect was not observed in males (Dalla et al., 2005). By con-
trast, ArKO males did not differ from WT in spontaneous motor
activity, exploration, or anxiety. These findings are in line with
the absence of major neurochemical alterations in hypothalamus,
prefrontal cortex, or striatum, which are involved in the expression
of these behaviors.
Clinical and community studies of women have shown that
both anxiety and depression are increased in women taking aro-
matase inhibitors for breast cancer (Mitwally and Casper, 2003;
Zivian and Salgado, 2008). Long-term efficacy and safety of the use
of AI in men and boys has not been established to date, although
sex differences in brain-related effects are likely due to the inher-
ently different implications of changing the estrogen/androgen
ratio in males and females and also because higher levels of testos-
terone in males compared to females renders it more difficult to
effectively inhibit aromatase in men (de Ronde and de Jong, 2011).
APPETITE
Prenatal exposure to nicotine appear to alter saccharin preferences
in a sexually dimorphic manner, eliminating an observation in
untreated animals where females had a higher preference to sac-
charin than untreated males. In the animals exposed to nicotine
prenatally, there was an increase in males preferring saccharin to
the female level (Lichtensteiger and Schlumpf, 1985). This study
provides another example of a demasculinizing effect of prenatal
nicotine as would be expected to result from prenatal aromatase
inhibition.
The situation is different in adults, where acute nicotine admin-
istration is considered to be a powerful appetite suppressant. In
fact, the effects of smoking on body weight are a concern since
more women than men report smoking to avoid weight gain
(Pomerleau and Kurth, 1996). This effect is at least partly biolog-
ically based since studies of Sprague-Dawley rats showed greater
effects of nicotine on food intake and body weight in female than
male rats (Grunberg, 1986). The appetite-suppressing effect of
nicotine appears to be mediated through direct interaction with
neurons involved in initiation of feeding behavior (Mineur et al.,
2011) and is not likely to be mediated through aromatase inhi-
bition, though other effects of nicotine related to appetite may
rely on this mechanism. Thus, nicotine appears to increase the
reinforcing properties of food (reviewed in Donny et al., 2011)
and older studies report increased consumption of sweet foods
following nicotine deprivation (Hughes et al., 1991; Spring et al.,
2003).
Estrogen is known to suppress feeding and weight gain in mam-
malian females including women. An important contribution to
this effect of estrogen is suppression of feeding by direct action
with brain centers engaged in appetite control (Nunez et al., 1980;
Butera and Beikirch, 1989; Dagnault and Richard, 1997; reviewed
in Geary, 2004). Consequently, inhibition of aromatase is expected
to increase feeding and weight gain, as reported by Kubatka et al.
(2008a,b) who found increased weight gain in female rats treated
with two different aromatase inhibitors – anastrozole and letro-
zole. Increased weight gain was reported by close to 50% of a
community sample of 1200 women taking aromatase inhibitors
for breast cancer (Zivian and Salgado, 2008). In the same vein, we
found a negative correlation between aromatase in the amygdala
and BMI, which was more pronounced in women than in men
(Wang et al., 2011). However it is noteworthy that loss of appetite
is also reported by some women receiving aromatase inhibitors
(Mitwally and Casper, 2003) amounting to 8% of responders in a
community sample (Zivian and Salgado, 2008). There appear to
be important sex differences in the control of food intake (Geary
and Lovejoy, 2008). Interestingly, in male rodents, peripubertal
inhibition of aromatase leads to a decrease rather than an increase
in body growth and weight gain (Bajpai et al., 2010).
HOT FLASHES
Current smoking (and high BMI), reportedly predispose women
to more severe or frequent hot flashes (Whiteman et al., 2003).
In perimenopausal women ages 45–54, current smokers had sig-
nificantly higher androstenedione levels and a higher androgen
to estrogen ratio than never smokers. Current smokers also had
lower progesterone levels and increased odds of experiencing hot
flushes compared to never smokers (Cochran et al., 2008). This
effects is sex specific since there are no reports on hot flushes
in healthy male smokers. It is noteworthy that men treated for
prostate cancer with androgen ablation therapy (e.g., by injec-
tions of gonadotropin-releasing hormone analogs) report daily
hot flashes, which respond to estrogen treatment (Gerber et al.,
2000).
Hot flashes are the most common adverse effect reported in
clinical trials and community studies of aromatase inhibitors in
women, with up to 75% of users reporting this adverse effect (Bon-
neterre et al., 2000; Mitwally and Casper, 2003; Howell et al., 2005;
Zivian and Salgado, 2008). Hot flashes arise when the thermoreg-
ulatory centers in the hypothalalmus are deprived of estrogen (see
review by Rossmanith and Ruebberdt, 2009) and are a classical
symptom of estrogen deprivation resulting from menopause and
ovariectomy as well as the most common side effect of estrogen
receptor antagonists and selective estrogen receptor modulators
like tamoxifen (e.g., Bonneterre et al., 2000; Howell et al., 2005).
COGNITION AND NEUROPROTECTION
Prenatal exposure to nicotine impairs cognitive functions, such
as memory and attention, and this impairment is gender-specific.
Deleterious effects in male but not female offspring were docu-
mented on synaptic function, cell signaling, and cell number. In
terms of cognitive performance, marked deficits were observed
in males in auditory attention (Niaura et al., 2001; Cornelius and
Day, 2009). Other studies show that on average, male smokers per-
form more poorly than female smokers on attention and memory
tasks (Abreu-Villaca et al., 2003; Jacobsen et al., 2007).
In females, stimulation of estrogen receptors, which enhances
hippocampal neurogenesis and synaptic plasticity, may be protec-
tive through providing greater adaptive capacity (Tanapat et al.,
1999; McEwen, 2002). However, this protection relative to males
is diminished in prenatally exposed rats who were treated with
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nicotine later in adolescence (Slotkin et al., 2007). Human studies
also documented that nicotine exposed females showed reduced
performance accuracy in neuropsychological tasks (Niaura et al.,
2001; Cornelius and Day, 2009).
A meta analysis of the acute effects of nicotine and smoking
on adult human performance found significant positive effects
of nicotine or smoking in several domains, including short-term
and working memory, with effect sizes ranging from 0.16 to 0.44
(Heishman et al., 2010). Treatment with nicotine receptor agonists
has been shown to elicit improvement of cognitive performance
in a variety of behavioral tests in rats, monkeys, and humans
(Reviewed in Mudo et al., 2007).
Evidence for the involvement of aromatase in support of cogni-
tive function and neuroprotection in various species was recently
reviewed by Garcia-Segura (2008) and Roselli et al. (2009). More
recently, AI were found to inhibit hippocampal learning (long-
term potentiation, LTP) and dendritic spine formation (Zhou
et al., 2010; Vierk et al., 2012) although the effects on LTP appear to
be sexually dimorphic, with significant effects found in female but
not male mice. In humans, a testosterone-supplementation study
in elderly men showed that the addition of an AI reversed the ben-
eficial effects of testosterone on verbal memory with no effect on
spatial memory (Cherrier et al., 2005). A similar study in women
did not reveal statistically significant effects of AI, although the
authors suggest the small size of the study may be a contributing
factor (Shah et al., 2006).
In preliminary studies at our laboratory, availability of aro-
matase in the amygdala was negatively correlated with perfor-
mance on verbal learning and memory tests in men, while in
women, aromatase in the amygdala was positively correlated with
high scores on trait constraint (Biegon et al., 2011a,b). Thus,
although there were no sex differences in aromatase availability
in amygdala or learning and memory scores nor traits in our sam-
ple, the amygdala aromatase availability was associated with sex
specific effects on verbal learning, memory, and personality traits.
ALZHEIMER’S DISEASE
Acute nicotine injections and chronic treatment with nicotine
patch have been found to improve attentional performance in
patients with Alzheimer’s Disease (AD; White and Levin, 1999).
The neural substrate for nicotine-induced improvement in atten-
tion is hypothesized to be related to the basal forebrain cholinergic
system (Lawrence and Sahakian, 1998).
Epidemiological studies initially indicating a lower incidence
of AD in smokers now suggest conflicting results. Clinical and
pathology findings also are mixed as to how smoking behavior
affects the manifestation of AD markers and the relevance of aro-
matase inhibition is unclear. Studies that show nicotine-induced
increases in nAChR and protection against age-related nAChR
decline, contrast perhaps in a functionally relevant way, to losses
of nAChR in AD. Although epidemiological, clinicopathological,
and functional studies in humans do not present a cohesive picture,
much in vitro data suggest neuroprotective properties of nicotine
when used in models of neurodegenerative disorders. Studies of
nicotine and nicotinic agonist effects on cognitive function in the
non-demented and in AD are not compelling. More work is needed
to ascertain whether acute or repetitive activation of nAChR with
acute or intermittent exposure to nicotine or the persistent inacti-
vation of nAChR with chronic nicotine exposure is a therapeutic
objective and/or explains any pro-cognitive effects of those drugs.
Other studies show complex interactions between nAChR, nico-
tinic agonists, and agents implicated in AD etiology (reviewed in
Sabbagh et al., 2002).
Aromatase has been suggested to play a role in AD (for review
see Hiltunen et al., 2006) although available data are not suffi-
cient to establish a neuroprotective effect. Human genetic studies
have revealed evidence of a relationship between mutations of the
aromatase gene and AD risk. Subjects who had single nucleotide
polymorphisms (SNPs) in the CYP19 gene were reported to have
an ∼60% increase in the risk for AD (Iivonen et al., 2004). Like-
wise, a twofold increased risk for AD was observed in ApoE ε4
carriers who had SNPs in the CYP19 gene (Huang and Poduslo,
2006). Studies on postmortem brains revealed enhanced aro-
matase expression in the nucleus basalis of Meynert and decreased
aromatase expression in the hypothalamus of AD patients, with
no sex differences observed in any of the nuclei studied (Ishunina
et al., 2005). In contrast, in hippocampus samples from women,
estrogen receptors (ERα subtype), and aromatase expression were
found to increase with age, and to decrease in AD (Ishunina et al.,
2007). An earlier study on frontal and temporal cortical samples
did not find significant difference in aromatase activity between
AD brains and controls (Wozniak et al., 1998).
ADDICTION
The rates of cigarette smoking have declined over the last few
decades, but smoking decreases among women are less pro-
nounced (Mathers and Loncar, 2006) and smoking rates among
girls and young women are increasing (CASA investigators, 2006).
Paralleling animal studies, human females appear to become
addicted faster than men, while finding it harder to quit (Bohadana
et al., 2003). In offspring of women who smoked during pregnancy,
the odds of progressing to nicotine dependence were almost dou-
bled compared to offspring from non-smoking women (Cornelius
and Day, 2009). Furthermore, nicotine replacement in the con-
text of smoking cessation appears to be less effective in women
(Bohadana et al., 2003; CASA investigators, 2006). A question
remains how or through what mechanism might cigarette smok-
ing become a gateway to smoking addiction and to other drugs.
Another question is how observed sex differences in smoking age
of onset and rates of smoking cessation may be related to the
actions of aromatase inhibition by smoking.
There is no evidence that aromatase inhibitors are addictive, in
stark contrast to the potent addictive properties of nictoine and
smoking (Nusbaum et al., 2000; Bohadana et al., 2003). However,
several lines of evidence suggest that aromatase may modulate
various aspects of nicotine addiction in a sex specific manner.
Addiction to other substances is also impacted. Female animals
consume more alcohol than males and interestingly, this effect is
reversible by gonadectomy (Almeida et al., 1998). This effect is not
restricted to alcohol but is also observed with psychostimulants as
cocaine.
Sex differences are also found in the context of relapse follow-
ing periods of abstinence, where as with cigarette smoking, females
find it harder to quit than males.
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Cigarette smoking is very common among drug addicted
individuals, and it appears that methadone, used to facilitate treat-
ment of opioid addiction, is metabolized by aromatase and may
act as a potent inhibitor of aromatase in vivo. These findings
may contribute to variability in methadone clearance, to drug–
drug interactions, and to side effects observed in male and female
patients. Because methadone seems to be able to inhibit aromatase,
it follows that methadone may alter the metabolism and dispo-
sition of endogenous testosterone and androstenedione. Lower
concentrations of estradiol have been documented in men taking
methadone (Hallinan et al., 2009), and low bone mineral density
that may be due to low estrogen concentrations has been docu-
mented in 83% of patients in a methadone maintenance treatment
program (Kim et al., 2006). It is conceivable that other side effects
of methadone, which include flushing, muscle pain, and symp-
toms reminiscent of estrogen withdrawal (Senay, 1985; Backstrom,
1995), may be explained in part by the drug’s action on aromatase.
DISCUSSION AND CONCLUSION
As shown above, aromatase and its activity in the brain can be
parsed to basic psychological processes; effects are observed in
affect, learning, and memory, libido, and appetite; and sex differ-
ences in the direction and size of the effects are very common. The
effects of smoking can also be parsed to the same psychological
processes, and sex differences in nicotine action have been recog-
nized in animals as well as human subjects (e.g., recent review by
Pogun and Yararbas, 2009).
This literature review highlights findings from animals and
humans indicating that smoking and nicotine target brain func-
tions which are also shaped and influenced by aromatase activity.
While it has been extensively documented that nicotine inter-
acts with the nicotinic acetylcholine receptor as its mechanism
of action, this does not exclude additional mechanisms contribut-
ing to the effects of smoking and nicotine on aggression, cogni-
tive function, anxiety, depression, sexual drive, and appetite (e.g.,
Fowler et al., 1996).
Available findings summarized above highlight the possibil-
ity that several of the known effects of nicotine, most prominently
effects on sexual and depression-like behavior and induction of hot
flashes, may be mediated or modulated by changes in aromatase
activity (Table 1) in an age- and sex-dependent manner. It is
noteworthy that these effects of nicotine are more prominent
in periods such as prenatal development, adolescence and the
perimenopausal period,which are associated with relatively abrupt
changes in estrogen synthesis (a prenatal peak in brain aromatase
in males, a peripubertal increase in ovarian production in girls
and a perimenopausal decrease in oarain production in adult
women). Such a profile is to be expected from a partial rather
than complete inhibition of aromatase activity exerted by nic-
toine and similar compounds which act as competitive inhibitors
of aromatase with low to moderate affinity (Barbieri et al., 1986;
Biegon et al., 2010a). Thus, we have shown that nicotine doses
producing plasma levels comparable with those found in smok-
ers are capable of a significant but partial (∼50%) inhibition
of aromatase. Obviously, more research is indicated to substan-
tiate and better understand the effects of aromatase inhibition
on brain function in this context. However, the notion that aro-
matase inhibition by nicotine and other tobacco alkaloids is an
alternative/additional mechanism for the effects of cigarette smok-
ing on human behavior, provides a mechanistic explanation to
observed sex differences in smoking and a possible source of new
treatment and prevention approaches for the initiation, physio-
logical and psychological consequences, and for the cessation of
smoking.
FUTURE PERSPECTIVES
While research on the brain effects and mechanisms of nicotine
action has been ongoing for many decades, specific AIs are rela-
tively new agents. Furthermore, despite the fact that several AIs are
approved drugs used in the clinical setting, the foremost clinical
use of these agents is in the adjuvant treatment of breast can-
cer (e.g., Buzdar and Howell, 2001), and clinical studies of breast
cancer do not include systematic investigation of neuropsycho-
logical effects. Consequently, there is a great need for additional
basic research on the effects of aromatase inhibition in males
and females across the life span. Such studies, as well as side-
by-side comparisons of aromatase inhibitors and nicotine and
other tobacco constituents have the potential to shed light on
sexually dimorphic effects in brain function and structure and
in important functioning domains such as mood, learning, and
memory. Since smoking addiction is replete with sex differences,
future exploration of sex specific, pharmacological interventions
targeting specific androgen, or estrogen receptors for prevention
or treatment is also warranted.
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